α cd40l

Manufactured by BioXCell

α‐CD40L is a recombinant protein that binds to the CD40 receptor. It is a key regulator of immune responses and can be used in various research applications.

Automatically generated - may contain errors

Lab products found in correlation

Ctla4 ig, by Bristol-Myers Squibb (1 mentions) Gentamicin sulfate, by MP Biomedicals (1 mentions) Hepes buffer, by MP Biomedicals (1 mentions) Clone pk136, by BioXCell (1 mentions) M199 medium, by Merck Group (1 mentions) Rapamycin, by LC Laboratories (1 mentions) α cd4, by BioXCell (1 mentions) αil 21r, by BioXCell (1 mentions) Fty720, by Cayman Chemical (1 mentions)

2 protocols using α cd40l

Induction of Mixed Chimerism in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

C57BL/6 recipient mice received 20 × 10⁶ unseparated BALB/c, B10.D2, CB6F1, or F1.BALB/c BM cells (d0). CD45.1 recipient mice were transplanted with 20 × 10⁶ unseparated BALB.B BM cells (d0). BM cells were collected from long and hip bones and preserved in M199 medium (Sigma‐Aldrich, St. Louis, MO) supplemented with 4 μg/mL Gentamicin Sulfate (MP Biomedicals, Irvine, CA) and 10 mM Hepes Buffer (MP Biomedicals). All BMT recipients additionally received CB consisting of α‐CD40L (1 mg: d0; clone MR1; Bio X Cell, West Lebanon, NH) and CTLA4‐Ig (0.5 mg: d2; Bristol‐Myers Squibb, New York, NY) and a short course of rapamycin (0.1 mg: d–1, d0, d2; LC Laboratories, Woburn, MA). Selected recipients of BALB/c, BALB.B, or B10.D2 BM additionally received α‐NK1.1 (0.25 mg: clone PK136; Bio X Cell) either at the time of transplantation (d–1, d2, d5, d8, short‐α‐NK1.1) or regularly until the end of follow‐up (d–1, d2, d5, d8, d28, d56, d84, 112, 140, 168) (long‐α‐NK1.1). Antibodies, fusion proteins, and rapamycin were administered intraperitoneally (i.p.). Mixed chimerism was defined as having at least 2 lineages displaying >0.5% donor cells.

Mahr B., Pilat N., Granofszky N., Muckenhuber M., Unger L.W., Weijler A.M., Wiletel M., Steiner R., Dorner L., Regele H, & Wekerle T. (2020). Distinct roles for major and minor antigen barriers in chimerism‐based tolerance under irradiation‐free conditions. American Journal of Transplantation, 21(3), 968-977.

+ Open protocol

+ Expand

Evaluating Immunotherapies in Influenza Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Influenza-infected WT mice were administrated with control IgG or various neutralizing or depleting Ab as described in the related Results sections. For CD4⁺ T cell depletion with high dose of α-CD4, mice were injected with 250 μg of α-CD4 weekly (clone: GK1.5, BioXCell) starting at 14 d.p.i. For circulating CD4⁺ T cell depletion, mice were intraperitoneally injected with 40 μg of α-CD4 for the first dose followed with 10 μg of α-CD4 weekly. CD40L blockade was achieved by the injection of 250 μg of α-CD40L (clone: MR-1, BioXCell) weekly, respectively. For systemic IL-21R blockade, 500 μg of α-IL21R (clone: 4A9, BioXCell) was injected intraperitoneally weekly starting at 14 d.p.i. For lung local IL-21R blockade, 50 μg of α-IL21R was injected through intranasal route weekly starting at 14 d.p.i. In some experiments, FTY720 (1 mg/kg; Cayman) was administrated via intraperitoneal injection daily from 13 d.p.i. to block lymphocyte migration until mouse euthanasia.

Son Y.M., Cheon I.S., Wu Y., Li C., Wang Z., Gao X., Chen Y., Takahashi Y., Fu Y.X., Dent A.L., Kaplan M.H., Taylor J.J., Cui W, & Sun J. (2021). Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses. Science immunology, 6(55), eabb6852.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!